Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    November 2021
  1. PREZIOSA P, Pagani E, Bonacchi R, Cacciaguerra L, et al
    In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI.
    J Neurol Neurosurg Psychiatry. 2021 Nov 19. pii: jnnp-2021-327803.
    PubMed     Abstract available


  2. NIJ BIJVANK J, Uitdehaag BMJ, Petzold A
    Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics.
    J Neurol Neurosurg Psychiatry. 2021 Nov 11. pii: jnnp-2021-327468.
    PubMed     Abstract available


    October 2021
  3. KONIG M, Lorentzen AR, Torgauten HM, Tran TT, et al
    Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
    J Neurol Neurosurg Psychiatry. 2021 Oct 20. pii: jnnp-2021-327612.
    PubMed     Abstract available


  4. MASUDA H, Mori M, Kuwabara S
    Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Oct 19. pii: jnnp-2021-326821.
    PubMed    


    August 2021
  5. DI FILIPPO M, Cordioli C, Malucchi S, Annovazzi P, et al
    mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Aug 18. pii: jnnp-2021-327200.
    PubMed    


  6. MONSCHEIN T, Hartung HP, Zrzavy T, Barnett M, et al
    Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.
    J Neurol Neurosurg Psychiatry. 2021 Aug 5. pii: jnnp-2021-326839.
    PubMed    


  7. LOUAPRE C, Ibrahim M, Maillart E, Abdi B, et al
    Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2021 Aug 2. pii: jnnp-2021-326904.
    PubMed     Abstract available


    July 2021
  8. MARGONI M, Villani U, Finos L, Franciotta S, et al
    Neurite orientation dispersion and density imaging discloses early changes in the normal-appearing white matter in paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jul 16. pii: jnnp-2021-326355.
    PubMed    


    June 2021
  9. WANG C, Barton J, Kyle K, Ly L, et al
    Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2021-326164.
    PubMed     Abstract available


    May 2021
  10. HEDSTROM AK, Hillert J, Olsson T, Alfredsson L, et al
    Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 May 13. pii: jnnp-2020-325688.
    PubMed     Abstract available


    April 2021
  11. COLATO E, Stutters J, Tur C, Narayanan S, et al
    Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes.
    J Neurol Neurosurg Psychiatry. 2021 Apr 20. pii: jnnp-2020-325610.
    PubMed     Abstract available


    March 2021
  12. HAIDER L, Chung K, Birch G, Eshaghi A, et al
    Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up.
    J Neurol Neurosurg Psychiatry. 2021 Mar 30. pii: jnnp-2020-325421.
    PubMed     Abstract available


  13. PFEUFFER S, Ruck T, Pul R, Rolfes L, et al
    Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
    J Neurol Neurosurg Psychiatry. 2021 Mar 12. pii: jnnp-2020-325304.
    PubMed     Abstract available


  14. HEDSTROM AK, Hillert J, Brenner N, Butt J, et al
    DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325676.
    PubMed     Abstract available


  15. MURPHY OC, Mukharesh L, Salazar-Camelo A, Pardo CA, et al
    Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis.
    J Neurol Neurosurg Psychiatry. 2021 Mar 9. pii: jnnp-2020-325274.
    PubMed     Abstract available


    February 2021
  16. KOCH-HENRIKSEN N
    It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease.
    J Neurol Neurosurg Psychiatry. 2021 Feb 9. pii: jnnp-2020-325684.
    PubMed    


    January 2021
  17. BURON MD, Kalincik T, Sellebjerg F, Sorensen PS, et al
    Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324869.
    PubMed     Abstract available


  18. PREZIOSA P, Bouman PM, Kiljan S, Steenwijk MD, et al
    Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2021 Jan 12. pii: jnnp-2020-324391.
    PubMed    


    November 2020
  19. WIJBURG MT, Warnke C, McGuigan C, Koralnik IJ, et al
    Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications.
    J Neurol Neurosurg Psychiatry. 2020 Nov 23. pii: jnnp-2020-324534.
    PubMed     Abstract available


  20. CUNNIFFE N, Vuong KA, Ainslie D, Baker D, et al
    Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Nov 12. pii: jnnp-2020-324286.
    PubMed     Abstract available


  21. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.
    PubMed    


    October 2020
  22. ZHUKOVSKY C, Sandgren S, Silfverberg T, Einarsdottir S, et al
    Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study.
    J Neurol Neurosurg Psychiatry. 2020 Oct 26. pii: jnnp-2020-323992.
    PubMed     Abstract available


  23. ANNUNZIATA P
    More time, more safety: is this the future optimal way for natalizumab treatment in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2020 Oct 21. pii: jnnp-2020-324032.
    PubMed    


  24. CHISARI CG, Grimaldi LM, Salemi G, Ragonese P, et al
    Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 14. pii: jnnp-2020-323472.
    PubMed     Abstract available


    August 2020
  25. EVANGELOU N, Garjani A, dasNair R, Hunter R, et al
    Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
    J Neurol Neurosurg Psychiatry. 2020 Aug 27. pii: jnnp-2020-324449.
    PubMed    


    July 2020
  26. COMPSTON A
    Review: Multiple sclerosis in the digital age: 'seeing through a glass darkly'.
    J Neurol Neurosurg Psychiatry. 2020 Jul 24. pii: jnnp-2020-323235.
    PubMed    


  27. CHISARI CG, Solaro C, Annunziata P, Bergamaschi R, et al
    Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
    J Neurol Neurosurg Psychiatry. 2020 Jul 13. pii: jnnp-2019-322480.
    PubMed     Abstract available


    June 2020
  28. BUTZKUEVEN H, Kappos L, Wiendl H, Trojano M, et al
    Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    J Neurol Neurosurg Psychiatry. 2020;91:660-668.
    PubMed     Abstract available


    May 2020
  29. ABRAHAMYAN S, Eberspacher B, Hoshi MM, Aly L, et al
    Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 May 5. pii: jnnp-2020-322941.
    PubMed     Abstract available


  30. PREZIOSA P, Rocca MA, Pagani E, Storelli L, et al
    Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    J Neurol Neurosurg Psychiatry. 2020;91:493-502.
    PubMed     Abstract available


    April 2020
  31. CHATAWAY J
    Distribution of plaques in the cerebrum in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Apr 20. pii: jnnp-2019-322431.
    PubMed    


    March 2020
  32. ARNOLD DL, Banwell B, Bar-Or A, Ghezzi A, et al
    Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322138.
    PubMed     Abstract available


  33. ESHAGHI A
    First approved treatment in children with multiple sclerosis slows brain atrophy.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322519.
    PubMed    


    February 2020
  34. GERALDES R, Jurynczyk M, Dos Passos G, Prichler A, et al
    Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Feb 7. pii: jnnp-2019-322369.
    PubMed     Abstract available


  35. LIU J, Mori M, Sugimoto K, Uzawa A, et al
    Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS.
    J Neurol Neurosurg Psychiatry. 2020;91:132-139.
    PubMed     Abstract available


    January 2020
  36. PROSPERINI L, Mancinelli C, Haggiag S, Cordioli C, et al
    Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Jan 23. pii: jnnp-2019-322348.
    PubMed     Abstract available


  37. SIMPSON S JR
    Keeping people with MS in the workforce through effective treatment.
    J Neurol Neurosurg Psychiatry. 2020;91:6.
    PubMed    


  38. ROMAN S
    Using clinically stable disease (NEDA 2) as a proxy for disease impact and employment in MS paints an incomplete picture.
    J Neurol Neurosurg Psychiatry. 2020;91:5.
    PubMed    


    November 2019
  39. CHALMER TA, Buron M, Illes Z, Papp V, et al
    Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Nov 14. pii: jnnp-2019-321523.
    PubMed     Abstract available


    May 2019
  40. TALLANTYRE EC, Major PC, Atherton MJ, Davies WA, et al
    How common is truly benign MS in a UK population?
    J Neurol Neurosurg Psychiatry. 2019;90:522-528.
    PubMed     Abstract available


    March 2019
  41. GIOVANNONI G
    The unintended consequences of NICE.
    J Neurol Neurosurg Psychiatry. 2019;90:247-248.
    PubMed    


  42. SCARPAZZA C, Signori A, Prosperini L, Sormani MP, et al
    Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.
    J Neurol Neurosurg Psychiatry. 2019;90:261-267.
    PubMed     Abstract available


    January 2019
  43. SORMANI MP, De Stefano N, Giovannoni G, Langdon D, et al
    Learning ability correlates with brain atrophy and disability progression in RRMS.
    J Neurol Neurosurg Psychiatry. 2019;90:38-43.
    PubMed     Abstract available


  44. WIJBURG MT, Warnke C, Barkhof F, Uitdehaag BMJ, et al
    Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    J Neurol Neurosurg Psychiatry. 2019;90:44-46.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: